Market Overview

Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, $11 Price Target, Neurocrine Biosciences with a Buy and $13 PT, Repros Therapeutics with Buy, $26 PT

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: Price Target Initiation Analyst Ratings

 

Most Popular

Related Articles (NBIX + RPRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free